Xenetic Biosciences Inc (XBIO):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C8294)
◆英語タイトル:Xenetic Biosciences Inc (XBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8294
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:38
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Xenetic Biosciences Inc (Xenetic Biosciences), formerly General Sales & Leasing Inc is a clinical-stage biopharmaceutical company that discovers and develops next-generation biologic drugs and novel orphan oncology therapeutics. The company’s pipeline products include Virexxa, ErepoXen, and OncoHist. Its lead product candidate ErepoXen is a polysialylated form of erythropoietin used to treat anemia in pre-dialysis patients with chronic kidney disease. Xenetic Biosciences’ Virexxa and OncoHist are used for the treatment of progesterone receptor negative endometrial cancer and refractory acute myeloid leukemia. The company also provides biologic drugs and innovative orphan cancer drugs. It has its operations in the US and the UK. Xenetic Biosciences is headquartered in Lexington, Massachusetts, the US.

Xenetic Biosciences Inc (XBIO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Xenetic Biosciences Acquires Rights to Virexxa from Kevelt 11
Partnerships 12
Xenetic Biosciences Enters into Agreement with Excivion 12
Licensing Agreements 13
Baxalta Enters into Licensing Agreement with Xenetic Biosciences 13
Equity Offering 14
Xenetic Biosciences Plans to Raise up to USD50 Million in Public Offering of Securities 14
Xenetic Biosciences Raises USD10 Million in Public Offering of Units 15
Xenetic Biosciences Raises USD10 Million in Private Placement of Shares 16
Xenetic Biosciences Raises USD0.3 Million in Private Placement of Shares 17
Debt Offering 18
Xenetic Biosciences Raises USD3 Million in Private Placement of 10% Notes 18
Acquisition 19
OPKO Health Acquires 6.3% Interest in Xenetic Biosciences 19
General Sales Completes Reverse Acquisition Transaction with Xenetic Biosciences 20
Xenetic Biosciences Completes Acquisition Of SymbioTec For US$14.4 Million 21
Xenetic Biosciences Inc – Key Competitors 22
Xenetic Biosciences Inc – Key Employees 23
Xenetic Biosciences Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Nov 15, 2017: Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update 25
Aug 15, 2017: Xenetic Biosciences Reports 2017 Second Quarter Financial Results and Provides Business Update 27
May 16, 2017: Xenetic Biosciences Reports 2017 First Quarter Financial Results and Provides Business Update 29
Apr 03, 2017: Xenetic Biosciences Reports 2016 Year End Financial Results and Provides Business Update 30
Corporate Communications 32
Oct 31, 2017: Xenetic Biosciences Appoints Jeffrey F. Eisenberg as Chief Executive Officer 32
Aug 14, 2017: Xenetic Biosciences Announces Appointment of Three Directors to the Board 33
Apr 04, 2017: Xenetic Biosciences Expands Executive Management Team with Appointment of James F. Parslow, MBA, CPA as Chief Financial Officer 34
Jan 04, 2017: Xenetic Biosciences Appoints Curtis A. Lockshin, Ph.D. as Chief Scientific Officer 35
Product News 36
Apr 20, 2017: Xenetic Biosciences’ PolyXen Platform Technology Accepted for Poster Presentation at the 13th Annual Protein Engineering Summit (PEGS) Boston 36
Other Significant Developments 37
Mar 27, 2017: Xenetic Biosciences Provides Update on Patent Portfolio Development 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Xenetic Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Xenetic Biosciences Acquires Rights to Virexxa from Kevelt 11
Xenetic Biosciences Enters into Agreement with Excivion 12
Baxalta Enters into Licensing Agreement with Xenetic Biosciences 13
Xenetic Biosciences Plans to Raise up to USD50 Million in Public Offering of Securities 14
Xenetic Biosciences Raises USD10 Million in Public Offering of Units 15
Xenetic Biosciences Raises USD10 Million in Private Placement of Shares 16
Xenetic Biosciences Raises USD0.3 Million in Private Placement of Shares 17
Xenetic Biosciences Raises USD3 Million in Private Placement of 10% Notes 18
OPKO Health Acquires 6.3% Interest in Xenetic Biosciences 19
General Sales Completes Reverse Acquisition Transaction with Xenetic Biosciences 20
Xenetic Biosciences Completes Acquisition Of SymbioTec For US$14.4 Million 21
Xenetic Biosciences Inc, Key Competitors 22
Xenetic Biosciences Inc, Key Employees 23
Xenetic Biosciences Inc, Subsidiaries 24

List of Figures
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Xenetic Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Xenetic Biosciences Inc (XBIO):製薬・医療:M&Aディール及び事業提携情報(Xenetic Biosciences Inc (XBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆